BALTIMORE, MD / ACCESSWIRE / February 14, 2019 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has released a new research report on fast-growing agriculture biotechnology provider Kiwa Bio-Tech Products Group Corp. (KWBT). The report features recent events and potential future share price valuations. To view this report, along with disclosures and disclaimers, or to download them in their entirety, please visit http://www.goldmanresearch.com.
Kiwa Bio-Tech Products Group Corp. develops, manufactures, markets and distributes innovative and environmentally safe bio-technological products for agriculture. Kiwa's focus is to positively impact the environment by reducing the amount of chemicals that are being used by agricultural growers in China. Kiwa products are covered by patent protection and are designed to enhance the quality of human life by increasing the value and productivity of agricultural crops.
In the Goldman Small Cap Research Opportunity Research report, analyst Rob Goldman offers key insights into Kiwa's fast-growing business and valuation.
Goldman noted, "There are four key factors in play with Kiwa which we believe will drive interest and valuation in these shares, going forward:"
Kiwa Bio-Tech is a pure play on the agbiotech industry in China
This opportunity represents a multi-billion-dollar global market. The Company's bio-fertilizers enhance the quality and productivity of crops while simultaneously reducing the negative environmental impact of chemicals currently used.
Broad, mandated replacement of chemicals with bio-fertilizers directly benefits Kiwa
Recent China government action plans to spur "green" agriculture development growth includes the replacement of chemical bio-fertilizers with bio-fertilizers on vegetables, fruits and teas planting. Kiwa is the beneficiary of new initiatives. These events leave Kiwa well-positioned to win new, low-hanging business from centers that represent billions in annual fertilizer sales.
Kiwa is recording enviable top-line growth; could up-list shares
"Kiwa is in the early stages of a major revenue and EPS boom, led by new and existing products and markets, beginning in 2019, which is why management is contemplating a share up-listing to a senior exchange." noted Goldman. Our model assumes 2018 and 2019 sales of $31.1M and $39.2M, respectively, with forecasted 2020 sales of $51.1M. We also project EPS will leap from $0.04 in 2018 to $0.18 in 2019 and $0.26 in 2020."
A relative unknown, Kiwa's financial performance will drive interest and valuation
"Against its industry backdrop, unique positioning, and financial performance, we believe Kiwa's shares are undervalued. Our 12-month target price is based on its 44.4% expected EPS growth rate ('19 - '20), which reflects a substantial increase in net profit margin, and yet low P/E and P/S ratios," remarked Goldman. "Furthermore, as a relative unknown to many small cap investors despite its recent operating performance, we expect even an incremental increase in volume will have a positive impact on the Kiwa share price, given its low shares outstanding."
About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.
Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.
This press release contains excerpts of our most recently published sponsored company research report on Kiwa Bio-Tech Products Group Corp. which carries a rating and a price target. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from Kiwa Bio-Tech Products Group Corp. ("the Company") authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.
Separate from the factual content of our report about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. To download this research report or any of our research, view our disclosures and disclaimers, or for more information, visit www.goldmanresearch.com. Goldman Small Cap Research was compensated $3500 by the Company for research and distribution services.
About Kiwa Biotech Products Group Corp.: Kiwa Bio-Tech Products Group Corp. (KWBT) develops, manufactures, markets and distributes innovative and environmentally safe bio-technological products for agriculture. Kiwa's focus is to positively impact the environment by reducing the amount of chemicals that are being used by agricultural growers in China. Kiwa products are covered by patent protection and are designed to enhance the quality of human life by increasing the value and productivity of agricultural crops.
For more information, please visit: www.KiwaBiotech.com
Goldman Small Cap Research
Rob Goldman, Analyst
SOURCE: Goldman Small Cap Research
View source version on accesswire.com: